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Progesterone in Women with Recurrent Miscarriages
To the Editor: In summarizing their well-exe-
cuted randomized trial, Progesterone in Recur-
rent Miscarriages (PROMISE), Coomarasamy et al. 
(Nov. 26 issue)1 state that there is no evidence of 
benefit from progesterone supplementation “in 
the first trimester” of pregnancy among women 
who have had three or more miscarriages. We 
wish to clarify three points. First, the trial did 
not address progesterone supplementation in 
women with coexisting subfertility. Nearly 33% 
of the women screened for the trial were exclud-
ed because of subfertility (515 of 1568 women). 
Second, because progesterone plays a key role in 
the implantation of the embryo, benefit from 
supplementation may be realized if progesterone 
is administered before and at the time of implan-
tation. In women undergoing fertility treatments, 
it is common to administer progesterone before 
and at the time of implantation,2 but in the trial 
by Coomarasamy et al., administration began af-
ter implantation. Third, a short luteal phase (<10 
days) is associated with a lower probability of 
clinical pregnancy, and it may also be associated 
with miscarriage.3,4 The correction of a luteal-
phase defect before implantation may improve 
the chance of ongoing pregnancy. The initiation 
of progesterone supplementation before preg-
nancy testing in women with subfertility, luteal-
phase defect, or both deserves further investiga-
tion to determine whether it would increase the 
chance of successful implantation and ongoing 
pregnancy.
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The authors reply: The purpose of the PROMISE 
trial was to examine the effects of progesterone 
supplementation in women who have had unex-
plained recurrent miscarriages. We did not in-
clude women with subfertility, and in fact women 
who did not conceive naturally within 1 year 
after recruitment were ineligible for randomi-
zation.
Our study focused on the use of progesterone 
in the first trimester of pregnancy and not in the 
luteal phase. The use of progesterone in the first 
trimester of pregnancy in women who have a 
history of unexplained recurrent miscarriages 
is widespread, although progesterone use in 
the luteal phase is rare. Our trial was designed 
to test current common practice. However, we 
agree that the question of whether to use pro-
gesterone in the luteal phase in women with 
unexplained recurrent miscarriages is important 
and requires further research. Such research will 
first require an improved understanding of lute-
al-phase defect; currently there are no accepted 
histologic, biochemical, proteomic, genomic, or 
other systems-biology–based techniques to iden-
tify luteal-phase defect, and a short cycle is only 
a crude marker of luteal-phase defect.
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